In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 701-708

  Milas, Luka ^a   Mason, Kathy ^a   Hunter, Nancy ^a   Petersen, Sven ^a   Yamakawa, Michitaka ^a   Ang, Kian ^b   Mendelsohn, John ^b   Fan, Zhen ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CELL SURVIVAL; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HUMANS; MALE; MICE; MICE, NUDE; NECROSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033966576     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 3: 2703-2707, 1997.
2. Hu, G., Liu, W., Mendelsohn, J., Ellis, L. M., Radinsky, R., Andreeff, M., and Deisseroth, A. B. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J. Natl. Cancer Inst., 89: 1271-1276, 1997.
3. Iihara, K., Shiozaki, H., Tahara, H., Kobayashi, K., Inoue, M., Tamura, S., Myata, M., Oka, H., Koki, Y., and Mori, T. Prognostic significance of transforming growth factor-α in esophageal carcinoma. Implication for the autocrine proliferation. Cancer (Phila.), 71: 2902-2909, 1993.
4. Grandis, J. R., Melham, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., and Tweardy, D. J. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst., 90: 824-832, 1998.
5. Klijin, J. G. M., Berns, P. M., Schmitz, P. I., and Foekens, J. A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev., 13: 3-17, 1992.
6. Dickstein, B. N., Wosikowski, K., and Bates, S. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell. Endocrinol., 110: 205-211, 1995.
7. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 80: 1605-1611, 1988.
8. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
9. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
10. Woodburn, J. R. The epidermal growth factor receptor and its inhibition in cancer treatment. Pharmacol. Ther., 82: 241-250, 1999.
11. Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst., 89: 341-343, 1997.
12. Zhu, A., Shaeffer, J., Leslie, S., Kolm, P., and El-Mahdi, A. M. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int. J. Radiat. Oncol. Biol. Phys., 34: 809-815, 1996.
13. Sheridan, M. T., O'Dwyer, T., Seymour, C. B., and Mothersill, C. E. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Invest., 5: 180-186, 1997.
14. Akimoto, T., Hunter, N. R., Buchmiller, L., Mason, K. A., Ang, K. K., and Milas, L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res., 5: 2884-2890, 1999.
15. Wollman, R., Yahalom, J., Maxy, R., Pinto, J., and Fuks, Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int. J. Radiat. Oncol. Biol. Phys., 30: 91-98, 1994.
16. Balaban, N., Moni, J., Shannon, M., Dang, L., Murphy, E., and Goldkorn, T. The effect of ionizing radialion on signal transduction: antibodies to EGF receptor sensilize A431 cells to radiation. Biochim. Biophys. Acta, 1314: 147-156, 1996.
17. Huang, S. M., Bock, J. M., and Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 59: 1935-1940, 1999.
18. Mendelsohn, J., Shin, D. M., Donato, N., Khuri, F., Radinsky, R., Glisson, B. S., Shin, H. J., Metz, E., Pfister, D., Perez-Soler, R., Lawhorn, K., Matsumoto, T., Gunnett, K., Falcey, J., Waksal, H., and Hong, W. K. A Phase I study of chimerized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC). Proc. Am. Soc. Clin. Oncol., 18: 389a, 1999.
19. Ezekiel, M. P., Robert, F., Meredith, R. F., Spencer, S. A., Newsome, J., Khazaeli, M. B., Peters, G. E., Saleh, M., LoBuglio, A. F., and Waksal, H. W. Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol., 17: 395a, 1998.
20. Fan, Z., Lu, Y., Wu, X., and Mendelsohn, J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem., 269: 27595-27602, 1994.
21. Wu, X., Fan, Z., Masui, H., Rosen, N., and Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest., 95: 1897-1905, 1995.
22. Prewett, M., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., Scher, H. I., and Goldstein, N. I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Emphasis Tumor Immunol., 19: 419-427, 1996.
23. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
24. Gregoire, V., Van, N. T., Stephens, L. C., Brock, W. A., Milas, L., Plunkett, W., and Hittelman, W. N. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res., 54: 6201-6209, 1994.
25. Stephens, L. C., Ang, K. K., Schultheiss, T. E., Milas, L., and Meyn, R. E. Apoptosis in irradiated murine tumors. Radiat. Res., 127: 308-16, 1991.
26. 2. Acta Oncol., 36: 183-189, 1997.
27. Runkel, S., Hunter, N., and Milas, L. An intradermal assay for quantification and kinetics studies of tumor angiogenesis in mice. Radiat. Res., 126: 237-43, 1991.
28. Milas, L., Furuta, Y., Hunter, N., Nishiguchi, I., and Runkel, S. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res., 50: 4473-4477, 1990.
29. Fan, Z., Masui, H., Altas, I., and Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 53: 4322-4328, 1993.
30. Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., and Weichselbaum, R. R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res., 59: 3374-3378, 1999.
31. Gorski, D. H., Mauceri, H. J., Salloum, R. M., Gately, S., Hellman, S., Beckett, M. A., Sukhatme, V. P., Soff, G. A., Kufe, D. W., and Weichselbaum, R. R. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res., 58: 5686-5689, 1998.
32. Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523-1530, 1997.
33. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., and Dinney, C. P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-265, 1999.
34. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M. J., Moyer, M. P., Neveu, M., Pollack, V. A., Pustilnik, L. R., Reynolds, M. M., Sloan, D., Theleman, A., and Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 57: 4838-4848, 1997.
35. Karnes, W. E., Jr., Weller, S. G., Adjei, P. N., Kottke, T. J., Glenn, K. S., Gores, G. J., and Kaufmann, S. H. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology, 114: 930-939, 1998.
36. Rodeck, U., Jost, M., Kari, C., Shih, D. T., Lavker, R. M., Ewert, D. L., and Jensen, P. J. EGF-R dependent regulation of keratinocyte survival. J. Cell Sci., 110: 113-121, 1997.
37. Modjtahedi, H., Affleck, K., Stubberfield, C., and Dean, C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induced apoptosis in the human squamous cell carcinoma HN5. Int. J. Oncol., 13: 335-342, 1998.
38. Schrieber, A. B., Winkler, M. E., and Derynck, R. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science (Washington DC), 232: 1250-1253, 1986.
39. Gille, J., Swerlick, R. A., and Caughman, S. W. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2 dependent DNA binding and transactivation. EMBO J., 16: 750-759, 1997.
40. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Hellmann, R., Gately, S., Dhanabal, M., Scott, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
41. Teicher, B. A., Holden, S. A., Dupuis, N. P., Kakeji, Y., Ikebe, M., Emi, Y., and Goff, D. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat., 56: 227-236, 1995.
42. Kakeji, Y., and Teicher, B. A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs, 15: 39-48, 1997.
43. Stockmeyer, B., Valerius, T., Repp, R., Heijnen, I. A., Buhring, H. J., Deo, Y. M., Kalden, J. R., Gramatzki, M., and van de Winkel, J. G. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res., 57: 696-701, 1997.